chronic myeloid leukemia - pmacpmac2019.com/uploads/post/pdf/pdf_post_dc8de4fbbf482.pdf · chronic...
TRANSCRIPT
![Page 1: Chronic Myeloid Leukemia - PMACpmac2019.com/uploads/post/PDF/pdf_post_dc8de4fbbf482.pdf · Chronic Myeloid Leukemia Brian Druker, MD Prince Mahidol Award Conference February 1, 2019](https://reader033.vdocuments.us/reader033/viewer/2022053001/5f05714e7e708231d412fc84/html5/thumbnails/1.jpg)
Chronic Myeloid Leukemia
Brian Druker, MD
Prince Mahidol Award Conference
February 1, 2019
Friday, February 1, 19
![Page 2: Chronic Myeloid Leukemia - PMACpmac2019.com/uploads/post/PDF/pdf_post_dc8de4fbbf482.pdf · Chronic Myeloid Leukemia Brian Druker, MD Prince Mahidol Award Conference February 1, 2019](https://reader033.vdocuments.us/reader033/viewer/2022053001/5f05714e7e708231d412fc84/html5/thumbnails/2.jpg)
• 15 - 20 % of all leukemias
Average age of onset - 50 to 60 yrs of age
Median survival – 3 to 5 years
• 1 - 2 cases per 100,000 per year
Chronic Myeloid Leukemia (CML)
Friday, February 1, 19
![Page 3: Chronic Myeloid Leukemia - PMACpmac2019.com/uploads/post/PDF/pdf_post_dc8de4fbbf482.pdf · Chronic Myeloid Leukemia Brian Druker, MD Prince Mahidol Award Conference February 1, 2019](https://reader033.vdocuments.us/reader033/viewer/2022053001/5f05714e7e708231d412fc84/html5/thumbnails/3.jpg)
Friday, February 1, 19
![Page 4: Chronic Myeloid Leukemia - PMACpmac2019.com/uploads/post/PDF/pdf_post_dc8de4fbbf482.pdf · Chronic Myeloid Leukemia Brian Druker, MD Prince Mahidol Award Conference February 1, 2019](https://reader033.vdocuments.us/reader033/viewer/2022053001/5f05714e7e708231d412fc84/html5/thumbnails/4.jpg)
Friday, February 1, 19
![Page 5: Chronic Myeloid Leukemia - PMACpmac2019.com/uploads/post/PDF/pdf_post_dc8de4fbbf482.pdf · Chronic Myeloid Leukemia Brian Druker, MD Prince Mahidol Award Conference February 1, 2019](https://reader033.vdocuments.us/reader033/viewer/2022053001/5f05714e7e708231d412fc84/html5/thumbnails/5.jpg)
BCR-ABL As a Therapeutic Target for CML
Friday, February 1, 19
![Page 6: Chronic Myeloid Leukemia - PMACpmac2019.com/uploads/post/PDF/pdf_post_dc8de4fbbf482.pdf · Chronic Myeloid Leukemia Brian Druker, MD Prince Mahidol Award Conference February 1, 2019](https://reader033.vdocuments.us/reader033/viewer/2022053001/5f05714e7e708231d412fc84/html5/thumbnails/6.jpg)
STI571 (CGP 57148B) Imatinib mesylate
GleevecTM, Glivec®
Friday, February 1, 19
![Page 7: Chronic Myeloid Leukemia - PMACpmac2019.com/uploads/post/PDF/pdf_post_dc8de4fbbf482.pdf · Chronic Myeloid Leukemia Brian Druker, MD Prince Mahidol Award Conference February 1, 2019](https://reader033.vdocuments.us/reader033/viewer/2022053001/5f05714e7e708231d412fc84/html5/thumbnails/7.jpg)
CML Summary
Friday, February 1, 19
![Page 8: Chronic Myeloid Leukemia - PMACpmac2019.com/uploads/post/PDF/pdf_post_dc8de4fbbf482.pdf · Chronic Myeloid Leukemia Brian Druker, MD Prince Mahidol Award Conference February 1, 2019](https://reader033.vdocuments.us/reader033/viewer/2022053001/5f05714e7e708231d412fc84/html5/thumbnails/8.jpg)
CML Summary
• There are currently 5 drugs on the market that target BCR-ABL
Friday, February 1, 19
![Page 9: Chronic Myeloid Leukemia - PMACpmac2019.com/uploads/post/PDF/pdf_post_dc8de4fbbf482.pdf · Chronic Myeloid Leukemia Brian Druker, MD Prince Mahidol Award Conference February 1, 2019](https://reader033.vdocuments.us/reader033/viewer/2022053001/5f05714e7e708231d412fc84/html5/thumbnails/9.jpg)
CML Summary
• There are currently 5 drugs on the market that target BCR-ABL
Friday, February 1, 19
![Page 10: Chronic Myeloid Leukemia - PMACpmac2019.com/uploads/post/PDF/pdf_post_dc8de4fbbf482.pdf · Chronic Myeloid Leukemia Brian Druker, MD Prince Mahidol Award Conference February 1, 2019](https://reader033.vdocuments.us/reader033/viewer/2022053001/5f05714e7e708231d412fc84/html5/thumbnails/10.jpg)
CML Summary
• There are currently 5 drugs on the market that target BCR-ABL
• Survival has been significantly prolonged
Friday, February 1, 19
![Page 11: Chronic Myeloid Leukemia - PMACpmac2019.com/uploads/post/PDF/pdf_post_dc8de4fbbf482.pdf · Chronic Myeloid Leukemia Brian Druker, MD Prince Mahidol Award Conference February 1, 2019](https://reader033.vdocuments.us/reader033/viewer/2022053001/5f05714e7e708231d412fc84/html5/thumbnails/11.jpg)
CML Life Expectancy
Boweretal,JClinOnc34:2851-7,2016
Friday, February 1, 19
![Page 12: Chronic Myeloid Leukemia - PMACpmac2019.com/uploads/post/PDF/pdf_post_dc8de4fbbf482.pdf · Chronic Myeloid Leukemia Brian Druker, MD Prince Mahidol Award Conference February 1, 2019](https://reader033.vdocuments.us/reader033/viewer/2022053001/5f05714e7e708231d412fc84/html5/thumbnails/12.jpg)
Since 2009 we have been working with the premise
“The improved survival in CML… is so dramatic that these new agents must be made available... As rapidly as possible throughout the whole world.”
Friday, February 1, 19
![Page 13: Chronic Myeloid Leukemia - PMACpmac2019.com/uploads/post/PDF/pdf_post_dc8de4fbbf482.pdf · Chronic Myeloid Leukemia Brian Druker, MD Prince Mahidol Award Conference February 1, 2019](https://reader033.vdocuments.us/reader033/viewer/2022053001/5f05714e7e708231d412fc84/html5/thumbnails/13.jpg)
As we look to the future
CML is predicted to become the most prevalent leukaemia by 2040 when there are projected to be over 3 million patients worldwide.
Friday, February 1, 19
![Page 14: Chronic Myeloid Leukemia - PMACpmac2019.com/uploads/post/PDF/pdf_post_dc8de4fbbf482.pdf · Chronic Myeloid Leukemia Brian Druker, MD Prince Mahidol Award Conference February 1, 2019](https://reader033.vdocuments.us/reader033/viewer/2022053001/5f05714e7e708231d412fc84/html5/thumbnails/14.jpg)
Global programs impact CML education, access to diagnostics and therapy
Enhancing patients survival around the world
Friday, February 1, 19
![Page 15: Chronic Myeloid Leukemia - PMACpmac2019.com/uploads/post/PDF/pdf_post_dc8de4fbbf482.pdf · Chronic Myeloid Leukemia Brian Druker, MD Prince Mahidol Award Conference February 1, 2019](https://reader033.vdocuments.us/reader033/viewer/2022053001/5f05714e7e708231d412fc84/html5/thumbnails/15.jpg)
Ourmissionistoincreaseglobalaccesstotreatment,careandsupportforpeoplelivingwithcancer.
InmemoryofMaxRivarola,1973-1991
Friday, February 1, 19
![Page 16: Chronic Myeloid Leukemia - PMACpmac2019.com/uploads/post/PDF/pdf_post_dc8de4fbbf482.pdf · Chronic Myeloid Leukemia Brian Druker, MD Prince Mahidol Award Conference February 1, 2019](https://reader033.vdocuments.us/reader033/viewer/2022053001/5f05714e7e708231d412fc84/html5/thumbnails/16.jpg)
The Max Access Solution ModelA patient centered system of humanitarian access to oncology treatment
HEALTHCAREPROVIDERSAnapprovednetworkofcancerspecialists
TREATMENTACCESSProcurementofqualitytargetedtreatment
LOGISTICS&DISTRIBUTIONEndtoendvalidated
supplychain
PATIENTSUPPORTAsupportsystem
aroundthepaMent
Friday, February 1, 19
![Page 17: Chronic Myeloid Leukemia - PMACpmac2019.com/uploads/post/PDF/pdf_post_dc8de4fbbf482.pdf · Chronic Myeloid Leukemia Brian Druker, MD Prince Mahidol Award Conference February 1, 2019](https://reader033.vdocuments.us/reader033/viewer/2022053001/5f05714e7e708231d412fc84/html5/thumbnails/17.jpg)
Max Access Solution for CML
72countries
30,000CML patientson treatment
600physicians
70Patient
associations3distribution
centers
Friday, February 1, 19
![Page 18: Chronic Myeloid Leukemia - PMACpmac2019.com/uploads/post/PDF/pdf_post_dc8de4fbbf482.pdf · Chronic Myeloid Leukemia Brian Druker, MD Prince Mahidol Award Conference February 1, 2019](https://reader033.vdocuments.us/reader033/viewer/2022053001/5f05714e7e708231d412fc84/html5/thumbnails/18.jpg)
Friday, February 1, 19
![Page 19: Chronic Myeloid Leukemia - PMACpmac2019.com/uploads/post/PDF/pdf_post_dc8de4fbbf482.pdf · Chronic Myeloid Leukemia Brian Druker, MD Prince Mahidol Award Conference February 1, 2019](https://reader033.vdocuments.us/reader033/viewer/2022053001/5f05714e7e708231d412fc84/html5/thumbnails/19.jpg)
Friday, February 1, 19